HanmiScience Reports 2Q Sales of 309.1 Billion Won... "We Will Accelerate Value-Up"

Hanmi Science, the holding company of Hanmi Pharmaceutical Group, announced on the 30th that it recorded provisional consolidated results for the second quarter of this year with sales of 309.096 billion KRW and an operating profit of 26.565 billion KRW. Compared to the same period last year, sales decreased by 2%, but operating profit increased by 0.5%.

On a cumulative basis for the first half of the year, sales reached 629.248 billion KRW, and operating profit was 63.868 billion KRW. These figures represent increases of 3.7% and 10.5%, respectively, compared to last year.

Looking at each affiliate, the core affiliate Hanmi Pharmaceutical recorded sales of 378.1 billion KRW in the second quarter, up 10.3% year-on-year, while its Chinese local subsidiary Beijing Hanmi Pharmaceutical posted sales of 98.7 billion KRW. JVM, a company specializing in automated pharmaceutical dispensing systems, reported sales of 37.7 billion KRW. Hanmi Science’s healthcare business segment recorded sales of 30.5 billion KRW, a 2.7% increase from the same period last year, and the pharmaceutical wholesale division (Online Pharm) posted sales of 265.3 billion KRW.

Lim Jong-hoon, CEO of Hanmi Science, said, "Over the past three months as the representative of Hanmi Science, we have accelerated efforts to enhance the value of the entire Hanmi Pharmaceutical Group affiliates, including Hanmi Pharmaceutical, Beijing Hanmi Pharmaceutical, Hanmi Precision Chemical, Online Pharm, and JVM," adding, "We will expand communication channels with the market and shareholders, promptly and positively review interim dividends, and accelerate the creation of new drug achievements and domination of the domestic specialized pharmaceutical market to further increase the intrinsic corporate value.”